How Biotech Is Using Synthetic Lethality to Target Cancer

In this episode of Biotech Business with Fexingo, Lucas and Luna explore synthetic lethality, a precision oncology approach that exploits cancer cells' unique genetic weaknesses. They focus on the PARP inhibitor story—how drugs like olaparib, originally developed by AstraZeneca and Myriad Genetics, turned a lab-bench concept into a multi-billion-dollar class of therapies. Lucas breaks down the science: two non-lethal mutations become lethal only when combined in a cancer cell, sparing healthy tissue. They discuss the commercial arc, from the 2014 FDA approval for BRCA-mutated ovarian cancer to today's expansion into pancreatic and prostate cancers. The episode also looks ahead to emerging targets like WEE1 and ATR inhibitors, and why big pharma is paying billions for startups that can identify new synthetic lethal pairs. A concrete look at how understanding genetics is rewriting oncology treatment protocols and creating lucrative niche markets. #SyntheticLethality #PARPInhibitors #Olaparib #BRCAMutation #Oncology #PrecisionMedicine #DrugDiscovery #Biotech #AstraZeneca #MyriadGenetics #Lynparza #DNARepair #CancerGenetics #WEE1Inhibitors #ATRInhibitors #Business #FexingoBusiness #BusinessPodcast Keep every episode free: buymeacoffee.com/fexingo